GO:0032305 positive regulation of icosanoid secretion: Lipid Mediator Secretion Control, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0032305 describes any process that activates or increases the frequency, rate or extent of the controlled release of an icosanoid from a cell.
• Icosanoids are oxygenated metabolites of arachidonic acid and related fatty acids, including prostaglandins, leukotrienes, thromboxanes, and hydroxyeicosatetraenoic acids (HETEs).
• Positive regulation of icosanoid secretion is central to inflammation, immune cell communication, platelet function, and bone homeostasis.
• Key molecular players include phospholipase A2 enzymes (e.g., PLA2G7), cyclooxygenases, lipoxygenases (e.g., ALOX12), prostaglandin transporters (e.g., SLCO2A1), and their receptors.
• Dysregulated icosanoid secretion contributes to cancer immune evasion, impaired T cell expansion, and metabolic disorders.
• CRISPR-based knockout, point-mutation, knock-in, and overexpression models enable causal dissection of genes controlling icosanoid secretion.
Description
Icosanoids are a family of bioactive lipid mediators derived from arachidonic acid and other polyunsaturated fatty acids. They include prostaglandins, thromboxanes, leukotrienes, and hydroxyeicosatetraenoic acids (HETEs), and they act locally to regulate inflammation, vascular tone, platelet aggregation, and immune cell function. The controlled release of these lipids from cells is not passive; it is a regulated secretory process that can be positively or negatively modulated. GO:0032305, positive regulation of icosanoid secretion, captures the biological processes that increase the frequency, rate, or extent of icosanoid release from a cell. Understanding this term is essential because icosanoid secretion sits at the interface of lipid metabolism, membrane transport, and intercellular signaling. For researchers, GO:0032305 provides a framework to annotate genes and pathways that amplify lipid mediator output, from phospholipase A2-mediated liberation of arachidonic acid to transporter-mediated export and receptor feedback. Recent studies show that icosanoid secretion is not merely a downstream consequence of inflammation but an active driver of disease. For example, cancer cells can impair monocyte-mediated T cell stimulation to evade immunity, a process linked to altered lipid mediator secretion. In another context, PGE2 inhibits tumor-infiltrating lymphocyte expansion by disrupting IL-2 signaling and mitochondrial function, highlighting how icosanoid release shapes immune responses. Thus, GO:0032305 is a focal point for understanding how cells communicate via lipid signals and how this communication can be therapeutically modulated.
positive regulation of icosanoid secretion At A Glance
| GO ID | GO:0032305 |
|---|---|
| GO term | positive regulation of icosanoid secretion |
| Ontology | biological_process |
| Synonym | activation of icosanoid secretion; positive regulation of eicosanoid secretion; stimulation of icosanoid secretion; up regulation of icosanoid secretion; up-regulation of icosanoid secretion; upregulation of icosanoid secretion |
| Major function | Increases the frequency, rate or extent of controlled release of icosanoids from a cell |
| Icosanoid examples | Prostaglandins (e.g., PGE2), leukotrienes, thromboxanes, HETEs (e.g., 12-HETE) |
| Key enzymes | Phospholipase A2 (e.g., PLA2G7), cyclooxygenases, lipoxygenases (e.g., ALOX12) |
| Transporters | Prostaglandin transporters such as SLCO2A1 and ABCC4 |
| Related processes | Arachidonic acid metabolism, inflammatory response, immune cell activation |
What Is GO:0032305?
GO:0032305, positive regulation of icosanoid secretion, is defined as any process that activates or increases the frequency, rate or extent of the controlled release of an icosanoid from a cell. In other words, it encompasses the molecular events that boost the export of lipid mediators such as prostaglandins, leukotrienes, and HETEs from their cell of origin. This term is a biological process and is distinct from the secretion itself; it specifically refers to the positive regulation of that secretion. Synonyms include activation of icosanoid secretion, positive regulation of eicosanoid secretion, stimulation of icosanoid secretion, and upregulation of icosanoid secretion.
Why Is positive regulation of icosanoid secretion Important in Cell Biology?
Positive regulation of icosanoid secretion is critically important because icosanoids are potent local hormones that control inflammation, immunity, hemostasis, and tissue homeostasis. Dysregulated secretion of these lipids underlies numerous pathological conditions, including cancer, chronic inflammatory diseases, and metabolic disorders. For instance, PGE2 secreted by tumor cells or myeloid cells can suppress T cell-mediated immunity and promote tumor progression. In bone, the PLA2G7/ALOX12/12-HETE/GPR31 signaling axis regulates bone homeostasis, demonstrating that icosanoid secretion is not limited to inflammation but also controls skeletal remodeling. Moreover, brown adipose tissue activation in humans increases plasma levels of lipid mediators, linking icosanoid secretion to systemic metabolism. Therefore, understanding GO:0032305 provides mechanistic insight into how cells amplify lipid mediator release and offers opportunities for therapeutic intervention.
• Icosanoid secretion is a key driver of acute and chronic inflammation, affecting diseases such as arthritis, asthma, and atherosclerosis.
• Prostaglandin E2 (PGE2) secreted by cancer cells or myeloid cells impairs T cell expansion and promotes immune evasion.
• The PLA2G7/ALOX12/12-HETE/GPR31 axis regulates bone homeostasis, linking icosanoid secretion to skeletal health.
• Brown adipose tissue activation increases plasma lipid mediators, connecting icosanoid secretion to metabolic regulation.
• Platelet function and thrombosis depend on thromboxane A2 secretion, a classic example of regulated icosanoid release.
• Tuft cells regulate immune responses through secretion of lipid mediators such as leukotrienes, highlighting roles in mucosal immunity.
• ENO1 promotes liver carcinogenesis through YAP1-dependent arachidonic acid metabolism, showing how metabolic reprogramming boosts icosanoid production.
• Prostaglandin transporters such as SLCO2A1 are essential for icosanoid secretion and are linked to human diseases.
• Targeting positive regulators of icosanoid secretion could enhance cancer immunotherapy or reduce pathological inflammation.
• CRISPR screens can identify novel regulators of icosanoid secretion, accelerating drug target discovery.
What Happens During positive regulation of icosanoid secretion?
Liberation of Arachidonic Acid from Membrane Phospholipids
In simple terms: The first step is cutting fatty acids out of the cell membrane so they can be turned into signaling molecules.
Icosanoid synthesis begins with the release of arachidonic acid from membrane phospholipids, primarily by phospholipase A2 (PLA2) enzymes. Positive regulation of icosanoid secretion often involves increased PLA2 activity or expression. For example, PLA2G7 (lipoprotein-associated phospholipase A2) regulates bone homeostasis via the ALOX12/12-HETE/GPR31 signaling axis, demonstrating that PLA2 activity is a control point for icosanoid production. Similarly, ENO1 promotes liver carcinogenesis through YAP1-dependent arachidonic acid metabolism, linking metabolic enzymes to arachidonic acid liberation. Thus, the first stage of positive regulation is the enhanced availability of free arachidonic acid.
Enzymatic Conversion to Bioactive Icosanoids
In simple terms: Once arachidonic acid is freed, enzymes like cyclooxygenases and lipoxygenases convert it into active lipid signals.
Free arachidonic acid is rapidly converted by cyclooxygenases (COX-1, COX-2), lipoxygenases (LOX), and cytochrome P450 epoxygenases into prostaglandins, thromboxanes, leukotrienes, and HETEs. Positive regulation of icosanoid secretion can occur through increased expression or activity of these enzymes. For instance, ALOX12 generates 12-HETE, which acts via GPR31 to regulate bone homeostasis. In cancer, PGE2 production is often elevated due to increased COX-2 expression, contributing to immune suppression. Therefore, the enzymatic conversion step is a major node for positive regulation.
Transport and Export of Icosanoids
In simple terms: After synthesis, lipid signals must be transported out of the cell to reach their targets.
Icosanoids are released from cells via specific transporters, including SLCO2A1 (prostaglandin transporter) and ABCC4 (MRP4). Prostaglandin transport is a regulated process that can be positively modulated by signaling pathways. For example, increased expression of SLCO2A1 enhances PGE2 secretion, which can then act on neighboring cells. In brown adipose tissue, activation increases plasma levels of lipid mediators, suggesting that export mechanisms are activated during thermogenesis. Thus, positive regulation of icosanoid secretion often involves upregulation of transporter activity or expression.
Receptor-Mediated Feedback and Amplification
In simple terms: Secreted lipid signals can act back on the same cell or nearby cells to amplify their own production.
Icosanoids often act via G-protein-coupled receptors (e.g., GPR31 for 12-HETE, EP receptors for PGE2) to stimulate further secretion. This positive feedback loop can amplify inflammatory responses. For example, PGE2 inhibits T cell expansion by disrupting IL-2 signaling and mitochondrial function, but it can also promote its own production in myeloid cells. In tuft cells, lipid mediators regulate immune responses, indicating that receptor-mediated feedback is important in mucosal immunity. Therefore, positive regulation of icosanoid secretion includes autocrine and paracrine amplification loops.
Integration with Cellular Stress and Metabolic Signals
In simple terms: Cellular stress and metabolic changes can boost the production and release of lipid signals.
Positive regulation of icosanoid secretion is integrated with cellular stress responses and metabolic reprogramming. For instance, ENO1 promotes liver carcinogenesis through YAP1-dependent arachidonic acid metabolism, linking glycolysis to lipid mediator production. Cancer cells can impair monocyte-mediated T cell stimulation to evade immunity, a process that involves altered lipid mediator secretion. Thus, metabolic and stress signaling pathways converge on icosanoid secretion to shape the immune microenvironment.
Key Genes Involved in GO:0032305 positive regulation of icosanoid secretion
The following genes and proteins are experimentally validated participants in the positive regulation of icosanoid secretion, based on published literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| PLA2G7 | Phospholipase A2 that liberates arachidonic acid; regulates bone homeostasis via ALOX12/12-HETE/GPR31 | Knockout models show bone phenotype; target for osteoporosis |
| ALOX12 | Lipoxygenase that generates 12-HETE from arachidonic acid | Key enzyme in icosanoid synthesis; linked to bone and inflammation |
| GPR31 | Receptor for 12-HETE; mediates signaling | Potential drug target for bone and inflammatory diseases |
| PTGS2 (COX-2) | Cyclooxygenase that produces prostaglandins from arachidonic acid | Overexpressed in cancer; target of NSAIDs |
| PTGS1 (COX-1) | Constitutive cyclooxygenase for prostaglandin synthesis | Housekeeping role in platelet and gastric function |
| SLCO2A1 | Prostaglandin transporter; mediates cellular export of PGE2 | Mutations cause primary hypertrophic osteoarthropathy |
| ABCC4 (MRP4) | ATP-binding cassette transporter; exports prostaglandins and leukotrienes | Multidrug resistance; regulates lipid mediator release |
| ENO1 | Enolase 1; promotes arachidonic acid metabolism via YAP1 | Oncogenic role in liver cancer; links glycolysis to lipid signaling |
| YAP1 | Transcriptional co-activator; drives arachidonic acid metabolism | Target in cancer; regulates icosanoid production |
| ALOX5 | 5-lipoxygenase; produces leukotrienes from arachidonic acid | Involved in asthma and inflammation |
| LTC4S | Leukotriene C4 synthase; conjugates LTA4 to glutathione | Key enzyme in cysteinyl leukotriene synthesis |
| PTGES | Prostaglandin E synthase; converts PGH2 to PGE2 | Target for inflammation and cancer |
| HPGD | 15-hydroxyprostaglandin dehydrogenase; degrades prostaglandins | Regulates PGE2 levels; tumor suppressor |
| PLA2G4A | Cytosolic phospholipase A2; releases arachidonic acid | Central to eicosanoid biosynthesis |
| TBXAS1 | Thromboxane A synthase; produces thromboxane A2 | Platelet function and cardiovascular disease |
| PTGIS | Prostacyclin synthase; produces prostacyclin (PGI2) | Vascular homeostasis |
| CYSLTR1 | Cysteinyl leukotriene receptor 1; mediates leukotriene signaling | Asthma and allergic diseases |
| PTGER2 | PGE2 receptor EP2; mediates PGE2 effects on immune cells | Cancer immunotherapy target |
How Is positive regulation of icosanoid secretion Regulated?
Positive regulation of icosanoid secretion is controlled at multiple levels. Transcriptional regulation of enzymes such as COX-2, PLA2G7, and ALOX12 can increase icosanoid output. Post-translational modifications, including phosphorylation, regulate the activity of phospholipases and cyclooxygenases. Transporters like SLCO2A1 and ABCC4 are regulated by signaling pathways and can be upregulated to enhance secretion. Metabolic signals, such as those mediated by YAP1 and ENO1, can boost arachidonic acid metabolism. In immune cells, receptor-mediated feedback via PGE2 and leukotrienes can amplify or dampen secretion. Additionally, brown adipose tissue activation increases plasma lipid mediators, indicating systemic regulation. Thus, positive regulation is a multilayered process integrating transcriptional, post-translational, and metabolic inputs.
positive regulation of icosanoid secretion and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| PLA2G7 | Bone homeostasis; osteoporosis | Knockout mouse; bone density analysis |
| PTGS2 (COX-2) | Cancer immune evasion; inflammation | Conditional knockout in myeloid cells; tumor models |
| SLCO2A1 | Primary hypertrophic osteoarthropathy | Knockout zebrafish or mouse; prostaglandin transport assays |
| ENO1 | Liver carcinogenesis | Liver-specific knockout; YAP1-dependent metabolism |
| ALOX12 | Bone remodeling; inflammation | Knockout mouse; 12-HETE measurement |
Cancer Immune Evasion
Cancer cells can impair monocyte-mediated T cell stimulation to evade immunity, a process linked to altered icosanoid secretion. PGE2 secreted by tumor cells or myeloid cells inhibits T cell expansion by disrupting IL-2 signaling and mitochondrial function. ENO1 promotes liver carcinogenesis through YAP1-dependent arachidonic acid metabolism, leading to increased icosanoid production. Therefore, positive regulators of icosanoid secretion are potential targets for cancer immunotherapy.
Bone Homeostasis and Skeletal Disorders
The PLA2G7/ALOX12/12-HETE/GPR31 signaling axis regulates bone homeostasis, demonstrating that icosanoid secretion is critical for skeletal remodeling. Dysregulation of this axis may contribute to osteoporosis or other bone diseases. Targeting positive regulators of icosanoid secretion could modulate bone mass.
Inflammatory and Immune Diseases
Icosanoids such as leukotrienes and prostaglandins are central to asthma, arthritis, and inflammatory bowel disease. Tuft cells regulate immune responses through secretion of lipid mediators, highlighting roles in mucosal immunity. Positive regulation of icosanoid secretion can exacerbate inflammation, making it a therapeutic target.
Metabolic Disorders
Brown adipose tissue activation in humans increases plasma levels of lipid mediators, linking icosanoid secretion to metabolic regulation. Dysregulated icosanoid secretion may contribute to obesity and insulin resistance. Thus, understanding positive regulation may offer metabolic disease interventions.
From positive regulation of icosanoid secretion-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of PLA2G7 reduce 12-HETE secretion and affect bone mass? | PLA2G7 knockout mouse |
| Can overexpression of SLCO2A1 enhance PGE2 export? | SLCO2A1 overexpression cell line |
| Does point mutation in ALOX12 alter enzymatic activity? | ALOX12 point-mutation knock-in |
| Does ENO1 knockout reduce arachidonic acid metabolism? | ENO1 knockout hepatocytes |
| Can CRISPR activation of COX-2 increase PGE2 secretion? | CRISPRa overexpression model |
| Does GPR31 knockout impair 12-HETE signaling? | GPR31 knockout mouse |
How to Study the positive regulation of icosanoid secretion Process
| Method | What It Measures | Typical Application |
|---|---|---|
| LC-MS/MS | Icosanoid levels in supernatants | Quantify PGE2, 12-HETE, leukotrienes |
| ELISA | Specific prostaglandin or leukotriene concentration | Measure PGE2 in cell culture |
| CRISPR knockout screen | Genes required for icosanoid secretion | Identify positive regulators |
| RNA-seq | Transcriptional changes in lipid metabolism genes | Profile ENO1/YAP1 effects |
| Proteomics | Protein expression of enzymes and transporters | Validate targets |
| Transport assay | Rate of prostaglandin export | Study SLCO2A1 function |
| Bone density analysis | Bone mass in knockout models | Assess PLA2G7/ALOX12 axis |
| T cell proliferation assay | T cell expansion in presence of PGE2 | Test immune suppression |
Lipid Mediator Quantification
Mass spectrometry (LC-MS/MS) is the gold standard for measuring icosanoids such as PGE2, 12-HETE, and leukotrienes in cell supernatants and plasma. This method allows precise quantification of secretion rates. ELISA kits are also used for specific prostaglandins.
Genetic Screens and CRISPR Libraries
Genome-wide CRISPR knockout or activation screens can identify positive regulators of icosanoid secretion. For example, screens in cancer cells have uncovered genes that modulate immune evasion via lipid mediators. These screens are powerful for discovering novel regulators.
Transcriptomic and Proteomic Profiling
RNA-seq and proteomics can reveal changes in expression of enzymes and transporters involved in icosanoid secretion. For instance, ENO1-dependent YAP1 activation alters arachidonic acid metabolism genes. Such profiling helps identify regulatory nodes.
Functional Secretion Assays
Cell-based assays measuring the release of fluorescent or radiolabeled arachidonic acid or prostaglandins can quantify secretion. Transport assays using SLCO2A1-expressing cells are used to study export. These assays are amenable to high-throughput screening.
How CRISPR Can Be Used to Study GO:0032305 positive regulation of icosanoid secretion
Knockout
CRISPR knockout of genes such as PLA2G7, ALOX12, or SLCO2A1 can abolish or reduce icosanoid secretion, providing causal evidence for their role. For example, PLA2G7 knockout mice exhibit bone phenotypes due to altered 12-HETE signaling. Knockout of PTGS2 in cancer cells reduces PGE2 secretion and may restore T cell function.
Point Mutation
Point mutations can be introduced to mimic disease-associated variants or to dissect catalytic residues. For instance, mutating the catalytic serine of ALOX12 can distinguish enzymatic activity from scaffolding functions. Such models are valuable for understanding how specific residues regulate icosanoid secretion.
Knock-in
Knock-in of tags (e.g., GFP, HA) or reporter genes allows visualization and tracking of proteins involved in icosanoid secretion. For example, knocking in a fluorescent tag on SLCO2A1 enables live-cell imaging of transporter localization. Knock-in of human disease mutations into mouse models can recapitulate human phenotypes.
Overexpression
CRISPR activation (CRISPRa) or cDNA overexpression can boost the expression of positive regulators such as COX-2 or SLCO2A1, leading to increased icosanoid secretion. This approach is useful for gain-of-function studies and for producing high levels of lipid mediators in vitro.
How EDITGENE Supports positive regulation of icosanoid secretion Research
Researchers studying positive regulation of icosanoid secretion-related genes often need to determine whether a candidate gene is causally involved in lipid mediator release, and to dissect the precise molecular mechanisms. EDITGENE provides a comprehensive suite of CRISPR-based services to enable such studies, from gene knockout to precise point mutations and overexpression.
Contact EDITGENE today to design your custom CRISPR model for positive regulation of icosanoid secretion research.
Frequently Asked Questions About positive regulation of icosanoid secretion
What is GO:0032305?
GO:0032305 is the Gene Ontology term for positive regulation of icosanoid secretion, defined as any process that activates or increases the frequency, rate or extent of the controlled release of an icosanoid from a cell.
What are icosanoids?
Icosanoids are oxygenated metabolites of arachidonic acid and related fatty acids, including prostaglandins, leukotrienes, thromboxanes, and HETEs.
What genes are involved in positive regulation of icosanoid secretion?
Key genes include PLA2G7, ALOX12, PTGS2 (COX-2), SLCO2A1, ABCC4, ENO1, and YAP1, among others.
How is icosanoid secretion regulated?
It is regulated at transcriptional, post-translational, and metabolic levels, involving enzymes like phospholipases and cyclooxygenases, transporters, and feedback via receptors.
Why is positive regulation of icosanoid secretion important in cancer?
It can promote immune evasion; for example, PGE2 secretion inhibits T cell expansion and helps tumors escape immunity.
What diseases are linked to icosanoid secretion?
Diseases include cancer, chronic inflammation, asthma, bone disorders, and metabolic diseases.
What methods are used to study icosanoid secretion?
LC-MS/MS, ELISA, CRISPR screens, RNA-seq, and transport assays are commonly used.
Can CRISPR be used to study icosanoid secretion?
Yes, CRISPR knockout, point mutation, knock-in, and overexpression models are powerful tools to dissect gene function in icosanoid secretion.
What is the role of PLA2G7 in icosanoid secretion?
PLA2G7 liberates arachidonic acid and regulates bone homeostasis via the ALOX12/12-HETE/GPR31 axis.
How does ENO1 affect icosanoid secretion?
ENO1 promotes liver carcinogenesis through YAP1-dependent arachidonic acid metabolism, increasing icosanoid production.
Conclusion
GO:0032305, positive regulation of icosanoid secretion, is a critical biological process that governs the release of lipid mediators such as prostaglandins, leukotrienes, and HETEs. These molecules play central roles in inflammation, immunity, bone homeostasis, and metabolism. Dysregulation of this process contributes to cancer immune evasion, chronic inflammatory diseases, and metabolic disorders. Understanding the genes and mechanisms that positively regulate icosanoid secretion offers opportunities for therapeutic intervention. CRISPR-based models, including knockout, point mutation, knock-in, and overexpression, are indispensable for dissecting these pathways. EDITGENE provides comprehensive services to support such research, from custom cell line generation to genome-wide screens and bioinformatics analysis.
References
- 1. Elewaut A et al.. 2025. Cancer cells impair monocyte-mediated T cell stimulation to evade immunity.. Nature 637(8046):716-725 PMID: 39604727
- 2. Sun L et al.. 2023. ENO1 promotes liver carcinogenesis through YAP1-dependent arachidonic acid metabolism.. Nat Chem Biol 19(12):1492-1503 PMID: 37500770
- 3. Jin J et al.. 2025. Pla2g7 regulates bone homeostasis via Alox12/12-HETE/Gpr31 signaling axis.. Nat Commun 16(1):11449 PMID: 41372218
- 4. Morotti M et al.. 2024. PGE(2) inhibits TIL expansion by disrupting IL-2 signalling and mitochondrial function.. Nature 629(8011):426-434 PMID: 38658764
- 5. Schuster VL. 2002. Prostaglandin transport.. Prostaglandins Other Lipid Mediat 68-69:633-47 PMID: 12432949
- 6. Walker ME et al.. 2024. Brown Adipose Tissue Activation in Humans Increases Plasma Levels of Lipid Mediators.. J Clin Endocrinol Metab 109(7):1837-1849 PMID: 38198796
- 7. Gerrard JM et al.. 1985. Platelet protein phosphorylation.. Adv Exp Med Biol 192:235-48 PMID: 3010667
- 8. Schneider C et al.. 2019. Regulation of immune responses by tuft cells.. Nat Rev Immunol 19(9):584-593 PMID: 31114038
